LAUSR

ABSTRACT Background Balovaptan is a potent, selective vasopressin 1a receptor antagonist. The early-phase pharmacokinetics (PK) of balovaptan are reported. Research design and methods Two Phase 1 studies (overall N = 93) assessed single- and multiple-dose balovaptan PK in healthy adults. One (N = 16) assessed absolute oral bioavailability (10 mg or 50 mg) vs a [13C]-balovaptan microdose. The other (N = 77) explored single- (0.5–76 mg) and multiple-dose (14 days; 12–52 mg/day) – randomized 6:2 balovaptan:placebo per dose – PK, dose proportionality, and the effect of food on single-dose (32 mg) Cmax and AUCinf. Results Absolute balovaptan bioavailability was high (103–116%). Steady-state (Day 14) balovaptan PK was approximately dose proportional with a half-life of 45–47 hours, but single-dose Cmax increased more than dose proportionally and half-life was inversely dose-proportional – a discordance partially attributable to a dose-and-time-dependent volume of distribution. Accumulation (Day 1–Day 14) was inversely dose-proportional (~3.5 [12 mg] to ~1.8 [52 mg]). There was no relevant effect of a high-fat meal on single-dose balovaptan exposure. There were no safety signals: 2/93 subjects discontinued for adverse events. Conclusions Balovaptan was well tolerated at single (≤76 mg) and multiple (≤52 mg/day) doses, with a PK profile supportive of once-daily administration without food restrictions. Trial registration ClinicalTrials.gov NCT03764449; NCT01418963.